Positive Role of Dutasteride in the Treatment of Localized Prostate Cancer.
- Author:
Jae Heon KIM
1
Author Information
1. Department of Urology, Soonchunhyang University Hospital, Soonchunhyang University School of Medicine, Seoul, Korea. piacekjh@hanmail.net
- Publication Type:Randomized Controlled Trial ; Original Article
- Keywords:
Dutasteride;
Prostate cancer
- MeSH:
Dihydrotestosterone;
Prostate*;
Prostatic Hyperplasia;
Prostatic Neoplasms*;
Recurrence;
Testosterone;
Urinary Tract;
Dutasteride
- From:Korean Journal of Urological Oncology
2015;13(1):24-28
- CountryRepublic of Korea
- Language:English
-
Abstract:
Dual inhibition of both 5AR1 and 5AR2 by dutasteride provides greater and more consistent inhibition of the conversion of testosterone to dihydrotestosterone (DHT) than selective inhibition of 5AR2 alone. Beyond the benefit of symptomatic improvement in lower urinary tract symptoms/benign prostatic hyperplasia by dutasteride, recently, several pioneering studies have shown cancer-protective roles of dutasteride in localized prostate cancer. This can be summarized into two categories: management of biochemical recurrence after radical therapy and management of active surveillance of low-risk prostate cancer. This review concerns the rationale and superiority of dutasteride as a cancer-protective agent in localized prostate cancer and its possible mechanisms, reinforced by two recent randomized controlled trials, the Avodart after radical therapy for prostate cancer study ("ARTS") and reduction by dutasteride of clinical progression events in expectant management ("REDEEM") studies.
